LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

embecta to Participate in Investor Conferences

May 15, 2023 | Last Trade: US$14.62 0.43 -2.86

PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:

2023 RBC Capital Markets Global Healthcare Conference

  • Management will host a fireside session on Tuesday, May 16, 2023, at 3:05 p.m. Eastern Time (ET) at the InterContinental Barclay, New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

2023 Jefferies Global Healthcare Conference

  • Management will host a fireside session on Thursday, Jun 8, 2023, at 3:30 p.m. Eastern Time (ET) at the Marriott Marquis, New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

About embecta 

embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

Media Investors 
Christian Glazar  Pravesh Khandelwal
Sr. Director, Corporate Communications    VP, Head of Investor Relations
908-821-6922 551-264-6547
This email address is being protected from spambots. You need JavaScript enabled to view it.      This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB